Neuroendocrine and cardiovascular effects of MDE in healthy volunteers

Neuropsychopharmacology. 1993 May;8(3):187-93. doi: 10.1038/npp.1993.20.


The drug 3,4-methylenedioxyethamphetamine ([MDE] also known as "Eve") is a less toxic analog of 3,4-methylenedioxymethamphetamine (also known as "Ecstasy") with similar psychotropic effects in humans. In a double-blind placebo-controlled, cross-over study we administered 140 mg of MDE or placebo orally to eight healthy male volunteers at 1:30 P.M. Serum cortisol, prolactin (PRL), and growth hormone (GH) levels, as well as blood pressure, and heart rate were measured every 20 minutes until 5:00 P.M. Administration of MDE was followed by statistically significant long-lasting increases of serum cortisol, PRL, systolic blood pressure, and heart rate, and by a trend toward blunting of GH secretion. The neuroendocrine and cardiovascular effects of MDE are comparable to those of other phenethylamines with the exception of the effect on GH secretion.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 3,4-Methylenedioxyamphetamine / analogs & derivatives*
  • 3,4-Methylenedioxyamphetamine / pharmacokinetics
  • 3,4-Methylenedioxyamphetamine / pharmacology
  • Adult
  • Blood Pressure / drug effects
  • Designer Drugs / pharmacokinetics
  • Designer Drugs / pharmacology*
  • Double-Blind Method
  • Heart Rate / drug effects
  • Hemodynamics / drug effects*
  • Hormones / blood*
  • Humans
  • Male
  • Middle Aged
  • Polysomnography


  • Designer Drugs
  • Hormones
  • 3,4-Methylenedioxyamphetamine
  • 3,4-methylenedioxyethamphetamine